BioNTech Offloads Roche R&D Costs From 2027 as Patent Suits Widen and Melbourne Plant Opens
Published on 11/17/2026 at 21:31 | Editorial boerse-global.deBioNTech has exercised an option in its collaboration with Roche/Genentech that will shift the bulk of future research and development spending onto its partner. From 1 January 2027, upcoming R&D costs in the joint programme are, in principle, to be borne by Roche/Genentech, the German biotech said on 3 November. Should the programme reach the market successfully, BioNTech retains the right to licensing payments.
The PDAC study already under way will continue as planned, according to the company. The cost reallocation applies specifically to the shared programme with Roche/Genentech.
A $205 Million Ticket for a Faster Review
Elsewhere on the regulatory front, BioNTech has agreed to buy a Priority Review Voucher from Scholar Rock for $205 million in cash. The company intends to deploy the voucher on a future marketing application drawn from its late-stage oncology pipeline. The deal remains subject to customary closing conditions, including antitrust clearance under the HSR process.
Should investors sell immediately? Or is it worth buying BioNTech?
Legal Pressure Builds on Two Continents
The quarter also brought fresh legal headaches. On 10 November, Arbutus Biopharma and Genevant expanded their Canadian patent lawsuit against Pfizer and BioNTech, adding a newly granted patent covering lipid nanoparticles, or LNP. The plaintiffs are seeking financial compensation and an injunction. Separately, the two companies filed additional patent suits in Japan targeting Pfizer Japan, again pursuing damages and an injunction.
Revenue Guidance Tightened at the Bottom
The legal and licensing news arrived alongside third-quarter 2026 results. BioNTech posted revenue of EUR 1.29 billion for the three months, with net profit of EUR 184.5 million. Management attributed the lower top line chiefly to an expected decline in demand for its COVID-19 vaccines. Guidance for adjusted R&D spending and for sales and administrative costs was left untouched.
Over the first nine months of 2026, revenue reached EUR 1.51 billion, while the bottom line showed a net loss of EUR 1.17 billion. For the full year, BioNTech raised the lower bound of its revenue forecast to a range of EUR 1.7 billion to EUR 1.9 billion, leaving the upper end unchanged.
Melbourne Site Takes Shape
On the infrastructure side, the company opened an mRNA production and research facility in Melbourne on 20 October. Located on the Bundoora campus of La Trobe University, the site is geared toward manufacturing at clinical scale.
Ad
BioNTech Stock: New Analysis - 17 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
